| A20 | Dasatinib inhibits provirus reactivation in patients co-infected with HIV and HCV | E-poster | Eliminating and silencing latency |
| A23 | Novel vector systems towards a cure for HIV/AIDS | E-poster | Gene therapy |
| A23 | Using the CRISPR-Cas9 system to cure cells from HIV and at the same time prevent super-infection by new HIV strains | E-poster | Gene therapy |
| A23 | Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a and b systems | E-poster | Gene therapy |
| A23 | A novel design algorithm to predict the silencing activity of siRNA | E-poster | Gene therapy |
| A25 | Increased platelet activation and inflammation markers associated to cardiovascular risk in HIV controllers | E-poster | HIV-1 controllers (including post-treatment controllers) and long-term non-progressors |
| A28 | Vaginal proteome signatures of unprotected sex | E-poster | Mechanism of transmission (mucosal, vertical, blood-borne) |
| A28 | Impact of acute sexual assault on female genital tract inflammation, psychological distress, and the association of increased risk of HIV | E-poster | Mechanism of transmission (mucosal, vertical, blood-borne) |
| A30 | Dysregulation of IFN-γ, TNF-a, IL-12 and IL-18 secretion in newly diagnosed individuals with HIV/TB co-infection | E-poster | Immune responses during acute HIV infection |
| A36 | Reactivity of plasma from HIV-infected pregnant women with recombinant Q β phages displaying the membrane proximal external region of HIV-1 envelope | E-poster | Novel vectors and strategies |